Amycretin

Status

In trials. Not approved. Novo Nordisk reported phase 3 initiation planned for 2026 for both formulations, under the name zenagamtide.

What it is

The former name of zenagamtide, a single molecule acting at the amylin and GLP-1 receptors; phase 3 planned for 2026.

What published research measured

Unlike CagriSema, which combines two peptides, amycretin is one unimolecular agonist at both receptors. Phase 1b/2a results in 125 adults published in The Lancet reported dose-dependent weight reduction with no plateau by the end of the treatment period. Phase 2 trials of the subcutaneous and oral forms in adults with type 2 diabetes followed (36 weeks; Lancet 2026, PMID 42532080), and Novo Nordisk reported phase 3 initiation planned for 2026 under the new name zenagamtide. Human data remain phase 2: this is not an established result.

Source

Dahl K et al. 2025 — Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase… · Gasiorek A et al. 2025 — Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist,… · Kuhre RE et al. 2025 — The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metab…

Sources

• Primary source
• Primary source
• CDC handling principles
• PubMed 42532080